There's More to Gilead Sciences' Remdesivir Data Than Meets the Eye @themotleyfool #stocks $GILD $FTSV https://t.co/JRxU0OFXyd Before the results of randomized controlled inpatient clinical trials the world's hopes weigh upon the shoulders of Gilead's remdesivir.